ABOUT AUTHORS:
Shujauddin Hashmi*,P. Neelkant reddy, S. hafiz ali, B. Kalyani, K. Karna, S. S.Biradar, Abdul kareem
Department of pharmacy practice
H.K.E Society’s Matoshree Taradevi Rampure Institute of Pharmaceutical Sciences,
MR medical College Road, Gulbarga -585105
ABSTRACT
Diabetes mellitus is a chronic and potentially disabling disease which is like a sleeping giant that is ready to awaken and literally sink our health care system. The present study “Pharmacoeconomic evaluation of anti-diabetic therapy” was carried out with an objective to assess estimated direct medical cost of diabetes and its complications. A hospital based prospective observational study was conducted using a prevalence based ‘cost of illness’ method focusing on estimated direct health care cost of diabetes and its complications. A total of 108 type 2 DM patients were enrolled into the study out of which 68 (62.96%) were males and 40 (37.04%) patients were females. The results revealed that, the average cost was the highest for the age group 45-60 years. The costs for patients with complications were substantially higher than those without complications and the costs were found to increase progressively with the increase in number of complications. The study concludes that Diabetes with complications resulted about 2.5 times higher cost, therefore the burden of diabetes and its complications was significant for individual and families, keeping in mind the burden of the disease on individuals as well as the society, the health policy makers should emphasize on initiatives to prevent the disease prevalence, care and counseling to diabetes patients should be done continuously to prevent the progression of the disease and its devastating complications.
